[Summary] Technology creates a healthy life
Shanghai Benemae Pharmaceutical Corporation Limited was founded in 1999, with its headquarters located in Shanghai. It is a high-tech enterprise dedicated to the independent research and development and industrialization of innovative biopharmaceuticals in the fields of endocrinology, cardiovascular diseases, and oncology. Its main products and products under research are all original new drugs independently discovered and developed. Over more than two decades, Benemae Bio has grown into a pioneer in innovative drug R&D for diabetes and has laid out a rich R&D pipeline in metabolism, cardiovascular, and oncology fields.
Yishengtai® Benaglutide injection is an innovative biological drug that took seventeen years of R&D to develop. Since its project initiation, it has successively been signed into major national research projects, including the National Major New Drug Creation Special Project by the Ministry of Science and Technology, Shanghai Strategic Emerging Industry Major Projects, and Shanghai Major Science and Technology Research Projects. Benaglutide injection is currently a GLP-1 class drug whose amino acid sequence is completely identical to that of human origin, primarily used for the treatment of type 2 diabetes. Its creation achieved a breakthrough in zero innovative drugs for diabetes in China. On December 28, 2020, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security issued the National Drug Catalogue for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (2020), and Yishengtai® Benaglutide injection was incorporated into the new medical insurance catalogue.
Since its establishment, the company has always adhered to the core values of "Patient first, Science based," insisted on continuous independent innovation, and actively served unmet clinical needs with solid technical platforms. Over more than twenty years of R&D journey, Benemae Bio has formed a series of core technical platforms covering innovative biopharmaceutical R&D including drug discovery, CMC, clinical research, and others, including target research and drug optimization, protein drug screening and evaluation, genetic engineering tandem expression, construction and screening of high-expression CHO cells, quality research of protein drugs, liquid formulation of biopharmaceuticals, and translational medicine. Benemae Bio has accumulated rich experience in new drug development and a large amount of research data in the field of innovative biopharmaceuticals, providing strong support for the enrichment of its future R&D pipeline. In the field of weight loss treatment, Benemae Bio's product under research, BEM-014, has obtained approval from China's NMPA and entered Phase III clinical trials, and also received clinical trial approval from the U.S. FDA, with clinical studies already initiated in the United States. In the conducted studies, BEM014 has shown clear weight reduction effects, and is expected to become a distinctive innovative drug (the first) for overweight/obesity indications in China in the future. In the field of non-alcoholic fatty liver disease/sthepatitis (NAFLD/NASH) treatment, Benemae Bio's product under research, BEM-050, is currently undergoing preclinical studies, and is about to apply for IND. In addition to laying out advantageous endocrine fields, Benemae Bio has also achieved promising R&D results in cardiovascular and oncology fields.
In the future, Benemae Bio will continue to increase investment in the R&D of original new drugs, build an internationally competitive technology platform, and thereby develop drugs with better efficacy and safety, so that the company's scientific research achievements can better serve more patients, and strive to help patients achieve the beautiful vision of reducing suffering, improving quality of life, and even prolonging life.
In 2014, Benemae Bio was listed on the National SME Share Transfer System, with stock code 830931. Currently, Benemae Bio is actively striving for listing on the Science and Technology Innovation Board.
We sincerely welcome outstanding talents who are willing to grow and develop together with Benemae Bio. Let us join hands and build a better tomorrow for Benemae Bio!
Company address: 916 Ziping Road, Pudong New Area, Shanghai (Shanghai International Medical Park)
Website:
What does Shanghai Benemae Pharmaceutical Corporation Limited require? Who is Benemae Bio hiring? Benemae Bio recruitment: 销售类占比最多占44.8%,其次是医疗卫生/美容保健类占38.8%. What education can get in at Benemae Bio? 大专占比最多占40.3%,其次是本科占38.8%. High education required at Benemae Bio? 硕士占16.4%,博士占1.5%. Work experience required at Benemae Bio? 1-3年占比最多占43.3%,其次是3-5年占26.9%. Where are the job locations at Benemae Bio? 上海占比最多占44.8%,其次是北京占22.4%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows